GlassScriptPhysician profile
Michael L Seigle
NPI 1639166259
$1,488.68
in general payments reported to CMS, 2019-2025
20 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $15.83 · 2021: $189 · 2022: $271 · 2023: $251 · 2024: $290 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $228.58 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $178.90 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $168.73 | 2022-2025 | Rocklatan, Tryptyr, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $113.88 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $98.73 | 2019-2025 | |
| Harrow Eye, LLC | $93.70 | 2024-2025 | Vevye |
| Thea Pharma INC. | $83.46 | 2022-2023 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $75.51 | 2021-2023 | |
| Shire North American Group INC | $61.13 | 2019 | |
| Horizon Therapeutics Plc | $58.73 | 2022-2023 | Tepezza |
| Amgen INC. | $51.06 | 2024-2025 | Tepezza |
| Allergan, INC. | $44.84 | 2021 | |
| Abbvie INC. | $44.27 | 2022 | |
| Aerie Pharmaceuticals, INC. | $42.48 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $36.75 | 2025 | Tecnis Iol |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn Operating Company LLC | $31.99 | 2021 | |
| Biotissue Holdings INC. | $25.21 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $18.21 | 2024 | Xdemvy |
| Immunogen, INC. | $17.82 | 2023 | Elahere |
| Astellas Pharma US INC | $14.70 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Seigle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.